Your browser doesn't support javascript.
loading
The landscape of chromothripsis across adult cancer types.
Voronina, Natalia; Wong, John K L; Hübschmann, Daniel; Hlevnjak, Mario; Uhrig, Sebastian; Heilig, Christoph E; Horak, Peter; Kreutzfeldt, Simon; Mock, Andreas; Stenzinger, Albrecht; Hutter, Barbara; Fröhlich, Martina; Brors, Benedikt; Jahn, Arne; Klink, Barbara; Gieldon, Laura; Sieverling, Lina; Feuerbach, Lars; Chudasama, Priya; Beck, Katja; Kroiss, Matthias; Heining, Christoph; Möhrmann, Lino; Fischer, Andrea; Schröck, Evelin; Glimm, Hanno; Zapatka, Marc; Lichter, Peter; Fröhling, Stefan; Ernst, Aurélie.
Afiliação
  • Voronina N; Group Genome Instability in Tumors, DKFZ, Heidelberg, Germany.
  • Wong JKL; Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
  • Hübschmann D; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Hlevnjak M; Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
  • Uhrig S; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Heilig CE; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Horak P; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
  • Kreutzfeldt S; Heidelberg Institute for Stem cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.
  • Mock A; Department of Pediatric Immunology, Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Stenzinger A; Division of Molecular Genetics, DKFZ, Heidelberg, Germany.
  • Hutter B; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
  • Fröhlich M; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
  • Brors B; Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.
  • Jahn A; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Klink B; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Gieldon L; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
  • Sieverling L; DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.
  • Feuerbach L; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Chudasama P; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
  • Beck K; DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.
  • Kroiss M; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Heining C; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
  • Möhrmann L; DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.
  • Fischer A; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Schröck E; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ, Heidelberg, Germany.
  • Glimm H; DKFZ-Heidelberg Center for Personalized Oncology (HIPO), Heidelberg, Germany.
  • Zapatka M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Lichter P; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
  • Fröhling S; Division of Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, Germany.
  • Ernst A; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases, DKFZ, Heidelberg, Germany.
Nat Commun ; 11(1): 2320, 2020 05 08.
Article em En | MEDLINE | ID: mdl-32385320
ABSTRACT
Chromothripsis is a recently identified mutational phenomenon, by which a presumably single catastrophic event generates extensive genomic rearrangements of one or a few chromosome(s). Considered as an early event in tumour development, this form of genome instability plays a prominent role in tumour onset. Chromothripsis prevalence might have been underestimated when using low-resolution methods, and pan-cancer studies based on sequencing are rare. Here we analyse chromothripsis in 28 tumour types covering all major adult cancers (634 tumours, 316 whole-genome and 318 whole-exome sequences). We show that chromothripsis affects a substantial proportion of human cancers, with a prevalence of 49% across all cases. Chromothripsis generates entity-specific genomic alterations driving tumour development, including clinically relevant druggable fusions. Chromothripsis is linked with specific telomere patterns and univocal mutational signatures in distinct tumour entities. Longitudinal analysis of chromothriptic patterns in 24 matched tumour pairs reveals insights in the clonal evolution of tumours with chromothripsis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromotripsia / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromotripsia / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha